BRIEF-Resverlogix announces positive recommendation from data safety monitoring board for Apabetalone phase 3 study

Thu Aug 11, 2016 7:45am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 11 (Reuters) - Resverlogix Corp

* Resverlogix announces positive recommendation from data safety monitoring board for phase 3 study of Apabetalone (rvx-208)

* Data review by independent data safety monitoring board resulted in verbal recommendation for Betonmace trial to continue as planned

* Dsmb reviewed available study data and noted that no safety or efficacy concerns were identified Source text for Eikon: Further company coverage: